Pharmaceutical Industry Related Content

CBD is at the forefront of pharmacology. So why has the European Commission changed its recommended status to “Narcotic”? Read on to find out more.

A new public health app by DRUID® measures factors to give an overall score of impairment, evolving the classic idea of drug testing.

Chair of the European Medicinal Cannabis Association (EUMCA) issues warning that raising limit for THC in CBD to 0.3% will risk patient safety.

Dr David Moorhouse, General Neurologist, discusses the way that different diseases respond to different types of medical cannabis.

Dr Daniela Tonucci, a consultant for over 10 years, talks us through the use of cannabinoids as pain medicine.

Professor Trevor Jones, Chair at the European Medicinal Cannabis Association, speaks to Nishat about their plans for EU patient access to medicinal cannabis.

David Shurtleff, PhD, Deputy Director at the National Center for Complementary and Integrative Health, National Institutes of Health, discusses new funding opportunities for cannabinoid research.

Open Access Government looks into the National Institute of General Medical Sciences (NIGMS)’s Biochemistry and Bio-related Chemistry Branch, and its current research areas and priorities.

Joseph Najjar and Andrew K. Udit, PhD from the Department of Chemistry at Occidental College enlighten us on the importance of Cytochromes P450 in medicine and industry.

Kathleen Denoodt shares with us what we need to know about the export of medicinal cannabis from Israel.

Neil Osheroff from the Vanderbilt University School of Medicine is working to overcome drug resistance and revitalise the use of established targets for antibacterial agents, as we discover here.

Prof Dr Freimut Schliess, Director of Science & Innovation at the Profil Institut für Stoffwechselforschung GmbH, shares a vision for remote decentralised clinical trials.

Dr Frank Wuest, Professor at Department of Oncology - University of Alberta, sheds light on the imaging biomarkers and the Alberta Radiopharmaceutical Collaboration in this special oncology focus.

Here, experts Stephan Pleschka, Oliver Planz and Stephan Ludwig walk us through the constant threat of influenza virus outbreaks and the benefit of enduring research in antiviral drug development.

Here, Ilesol Pharmaceuticals discuss how they became the first European cannabinoid company to unlock this sector of the market.

Michael Morrison, Senior Researcher in Social Science at the University of Oxford, illustrates the importance of emerging biomedical innovations in the UK.

Here, OilsBySimpson Founder Kevin William Simpson, explains what current research shows about CBD’s effect on epilepsy and its applications as a treatment.

Jay Sibbitts, Shu Jia, Obdulia Covarrubias-Zambrano, Stefan H. Bossmann and Christopher T Culbertson from Kansas State University’s Department of Chemistry walk us through what we need to know about microfluidic devices for detecting pain.

Scientists at TCS designed novel chemical compounds using AI that can inhibit the 3CL protease of SARS-CoV-2, which is responsible for viral replication. Ananth Krishnan, Chief Technology Office, TCS, discusses the research here.

Several drugs used for curing hepatitis C have been identified as potential candidates to treat COVID-19, according to research conducted using the MOGON II supercomputer at Johannes Gutenberg University Mainz.